2024-03-28 | NDAQ:ITRM | Press Release | Iterum Therapeutics

(2024-03-28 | NDAQ:ITRM) Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Related Keywords

Chicago , Illinois , United States , Dublin , Ireland , Iterum Closecurlyquote , Corey Fishman , Judy Matthews , Drug Administration , Recourse Royalty , Nasdaq , Cash Runway , Chief Executive , Special Protocol Assessment , Resistant Enterobacterales , Complete Response Letter , Financial Advisor , Full Year , Prescription Drug User Fee Act , Linked Notes Closecurlydoublequote , Exchangeable Senior Subordinated Notes , Notes Closecurlydoublequote , Iterum Therapeutics , Qualified Infectious Disease Product , Fast Track , Exchangeable Notes , Maturity Date Closecurlydoublequote , Royalty Linked Notes , Maturity Date , Private Securities Litigation Reform Act , Nasdaq Capital Market , Factors Closecurlydoublequote , Annual Report , Financial Officer , Consolidated Statement ,